ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+4.74%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$485M
AUM Growth
+$485M
(-19%)
Cap. Flow
-$74.8M
Cap. Flow
% of AUM
-15.41%
Top 10 Holdings %
Top 10 Hldgs %
49.77%
Holding
309
New
41
Increased
54
Reduced
66
Closed
104
Top Buys
| 1 |
Inhibikase Therapeutics
IKT
|
$16.6M |
| 2 |
Zai Lab
ZLAB
|
$13.4M |
| 3 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$10.1M |
| 4 |
ABVX
Abivax
ABVX
|
$7.26M |
| 5 |
AVR
Anteris Technologies Global Corp. Common Stock
AVR
|
$5.88M |
Top Sells
| 1 |
Royalty Pharma
RPRX
|
$26.7M |
| 2 |
Cytokinetics
CYTK
|
$23.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$21.1M |
| 4 |
Ascendis Pharma
ASND
|
$12.4M |
| 5 |
Immunovant
IMVT
|
$8.53M |
Sector Composition
| 1 | Healthcare | 80.2% |
| 2 | Financials | 3.47% |
| 3 | Communication Services | 1.36% |
| 4 | Utilities | 0.04% |
| 5 | Energy | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Exact Sciences
EXAS
$8.98B
| $281K | 0.06% |
5,000
-10,200
| -67% | -$573K |
|
127
Ventyx Biosciences
VTYX
$171M
| $273K | 0.05% |
124,530
+26,575
| +27% | +$58.2K |
|
128
Alvotech
ALVO
$2.51B
| $273K | 0.05% |
+20,600
| New | +$273K |
|
129
Wave Life Sciences
WVE
$1.53B
| $268K | 0.05% |
+21,700
| New | +$268K |
|
130
Gossamer Bio
GOSS
$562M
| $267K | 0.05% |
295,613
-121,345
| -29% | -$110K |
|
131
Quince Therapeutics
QNCX
$85.9M
| $267K | 0.05% |
142,958
| – | – |
|
132
Disc Medicine
IRON
$2.07B
| $266K | 0.05% |
4,196
-18,368
| -81% | -$1.16M |
|
133
BioCryst Pharmaceuticals
BCRX
$1.74B
| $263K | 0.05% |
35,000
| – | – |
|
134
Iron Horse Acquisitions Corp
IROH
$21.2M
| $257K | 0.05% |
25,000
| – | – |
|
135
RenovoRx
RNXT
$35.2M
| $254K | 0.05% |
197,250
-117,942
| -37% | -$152K |
|
136
PolyPid
PYPD
$53.3M
| $243K | 0.05% |
80,080
-13,822
| -15% | -$42K |
|
137
Merck
MRK
$210B
| $243K | 0.05% |
2,440
+1,300
| +114% | +$129K |
|
138
Arrowhead Research
ARWR
$3.05B
| $243K | 0.05% |
12,900
+1,195
| +10% | +$22.5K |
|
139
Kodiak Sciences
KOD
$478M
| $236K | 0.05% |
+23,700
| New | +$236K |
|
140
TherapeuticsMD
TXMD
$12.8M
| $232K | 0.05% |
270,160
| – | – |
|
141
Tenax Therapeutics
TENX
$27.3M
| $215K | 0.04% |
34,693
-27,730
| -44% | -$172K |
|
|
INZY
142
DELISTED
Inozyme Pharma
INZY
| $211K | 0.04% |
+76,299
| New | +$211K |
|
143
Nurix Therapeutics
NRIX
$714M
| $207K | 0.04% |
+11,000
| New | +$207K |
|
144
Pulmonx
LUNG
$69.7M
| $192K | 0.04% |
+28,221
| New | +$192K |
|
145
Ginkgo Bioworks
DNA
$750M
| $183K | 0.04% |
+18,680
| New | +$183K |
|
146
Algonquin Power & Utilities
AQN
$4.45B
| $178K | 0.04% |
40,000
-40,000
| -50% | -$178K |
|
147
uniQure
QURE
$896M
| $177K | 0.04% |
+10,000
| New | +$177K |
|
148
Cellectar Biosciences
CLRB
$15.5M
| $175K | 0.04% |
585,261
-436,900
| -43% | -$131K |
|
149
Anavex Life Sciences
AVXL
$828M
| $174K | 0.03% |
+16,221
| New | +$174K |
|
150
MindMed
MNMD
$676M
| $174K | 0.03% |
+25,000
| New | +$174K |
|